Kerstin Hermelink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9570466/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. Psycho-Oncology, 2022, 31, 770-778.	2.3	4
2	Late Presentation at Primary Diagnosis of Breast Cancer: Patients' Personality Characteristics and Attitudes. Breast Care, 2021, 16, 343-349.	1.4	0
3	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. Breast Cancer: Targets and Therapy, 2019, Volume 11, 87-97.	1.8	13
4	Dopamine synthesis and dopamine receptor expression are disturbed in recurrent miscarriages. Endocrine Connections, 2018, 7, 727-738.	1.9	8
5	TAAR1 induces a disturbed GSK3Î ² phosphorylation in recurrent miscarriages through the ODC. Endocrine Connections, 2018, 7, 372-384.	1.9	10
6	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. Breast Care, 2018, 13, 124-128.	1.4	4
7	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer, 2018, 18, 431.	2.6	15
8	Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psycho-Oncology, 2017, 26, 74-80.	2.3	53
9	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1637-1647.	2.5	29
10	Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. Journal of the National Cancer Institute, 2017, 109, .	6.3	73
11	RE: Post-traumatic Stress as the Primary Cause for Cognitive Decline—Not the Whole Story, and Perhaps No Story at All. Journal of the National Cancer Institute, 2017, 109, .	6.3	1
12	Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer. Oncotarget, 2017, 8, 105356-105371.	1.8	10
13	Response. Journal of the National Cancer Institute, 2016, 108, djw049.	6.3	1
14	Alleviating the Breast Cancer Experience: A Plea for Psycho-Oncology. Breast Care, 2015, 10, 82-83.	1.4	2
15	Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress. Journal of the National Cancer Institute, 2015, 107, djv099-djv099.	6.3	73
16	Chemotherapy and Cognitive Function in Breast Cancer Patients: The So-Called Chemo Brain. Journal of the National Cancer Institute Monographs, 2015, 2015, 67-69.	2.1	69
17	Brief Distress Screening in Clinical Practice: Does it Help to Effectively Allocate Psycho-Oncological Support to Female Cancer Inpatients?. Breast Care, 2014, 9, 129-129.	1.4	3
18	Chemobrain? – BeeintrÃ ë htigungen kognitiver Funktionen im Zusammenhang mit Erkrankung und		0

Therapie. , 2013, , 79-82.

KERSTIN HERMELINK

#	Article	IF	CITATIONS
19	Listening: Reflections on a Series of Counseling Sessions. Journal of Clinical Oncology, 2012, 30, 558-559.	1.6	2
20	Menopausal Status in Breast Cancer Patients with Past Chemotherapy Determines Long-Term Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2011, 8, 1486-1494.	0.6	35
21	Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 2011, 117, 1103-1103.	4.1	14
22	Two different sides of â€~chemobrain': determinants and nondeterminants of selfâ€perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology, 2010, 19, 1321-1328.	2.3	110
23	Chemobrain? – Kognitive Störungen nach Chemotherapie. , 2009, , 67-69.		1
24	Shortâ€ŧerm effects of treatmentâ€induced hormonal changes on cognitive function in breast cancer patients. Cancer, 2008, 113, 2431-2439.	4.1	83
25	Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer, 2007, 109, 1905-1913.	4.1	316
26	Immunotherapy: new options in breast cancer treatment. Expert Review of Anticancer Therapy, 2003, 3, 403-408.	2.4	26